fda warning letter compounded semaglutide september 2025 U.S. sends drug advertising letters to Lilly, Novo, Hims The FDA has approved a

Well-crafted Go-to-Market strategy With a large self-pay market, the need for differentiated direct-to-consumer engagement models will become more prevalent as a distinct yet complementary approach to traditional payer-driven models

Yet Lillys sales growth suggests a quickly closing gap, with Mounjaros 71% quarterly growth and Zepbounds 140% quarterly increase

Recommendation While international purchasing might seem appealing given price differences, the safety risks, legal uncertainty, lack of recourse if problems occur, and potential for counterfeit products make this approach not advisable

STEP 1 reported nausea in 44% of semaglutide patients versus 18% on placebo

They can guide you to choose a suitable supplement based on your medical history and goals